Commonly reported side effects of darunavir include: skin rash. Other side effects include: nausea.  See below for a comprehensive list of adverse effects.
Most side effects reported during therapy with darunavir/ritonavir were mild in severity.  The most common side effects were diarrhea, nausea, vomiting, headache, rash, and abdominal pain.  Adverse events led to therapy discontinuation in 2.3% and 4.7% of therapy-naive and therapy-experienced subjects, respectively, in randomized trials.The most common side effects reported with darunavir/cobicistat were diarrhea, nausea, and rash.  The manufacturer product information for cobicistat should be consulted.
Elevated pancreatic amylase (Grade 2: up to 7.4%; Grade 3: up to 7.8%; Grade 4: up to 1.1%) and pancreatic lipase (Grade 2: 5.2%; Grade 3: up to 2.6%; Grade 4: less than 1%) have been reported with darunavir/ritonavir.
Darunavir/ritonavir:-Very common (10% or more): Diarrhea (up to 14.4%)-Common (1% to 10%): Nausea, vomiting, abdominal pain, elevated pancreatic amylase, elevated pancreatic lipase, abdominal distension, dyspepsia, flatulence, elevated blood amylase-Uncommon (0.1% to 1%): Pancreatitis, acute pancreatitis, gastritis, gastroesophageal reflux disease, aphthous stomatitis, retching, dry mouth, abdominal discomfort, constipation, elevated lipase, eructation, oral dysesthesia-Rare (less than 0.1%): Stomatitis, hematemesis, cheilitis, dry lip, coated tongue-Frequency not reported: Elevated pancreatic enzymeDarunavir/cobicistat:-Very common (10% or more): Diarrhea (28%), nausea (23%)-Common (1% to 10%): Vomiting, abdominal pain, abdominal distension, dyspepsia, flatulence, increased pancreatic enzymes-Uncommon (0.1% to 1%): Acute pancreatitis
Darunavir/ritonavir:-Very common (10% or more): Elevated total cholesterol (up to 25%), elevated glucose levels (up to 15.4%), elevated low-density lipoprotein cholesterol (up to 14.4%), elevated triglycerides (up to 10.4%)-Common (1% to 10%): Hyperlipidemia, anorexia, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia-Uncommon (0.1% to 1%): Gout, decreased appetite, polydipsia, decreased weight, increased weight, hyperglycemia, insulin resistance, decreased high density lipoprotein, increased appetite, elevated LDH-Frequency not reported: Hypoglycemia, hyperuricemia, decreased bicarbonate, hypocalcemia, hyponatremia, hypernatremia, obesity, hypoalbuminemia-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia, ketoacidosis, redistribution of body fatDarunavir/cobicistat:-Common (1% to 10%): Anorexia, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, hyperlipidemiaCombination antiretroviral therapy:-Frequency not reported: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance"), metabolic abnormalities (such as hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia, hyperlactatemia)HIV protease inhibitor therapy:-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes, hyperglycemia, diabetic ketoacidosis
Elevated total cholesterol (Grade 2: up to 25%; Grade 3: up to 10%), glucose levels (Grade 2: up to 15.4%; Grade 3: up to 1.7%; Grade 4: less than 1%), low-density lipoprotein cholesterol (Grade 2: 14.4%; Grade 3: up to 9.1%), and triglycerides (Grade 2: up to 10.4%; Grade 3: up to 8.2%; Grade 4: up to 3.9%) have been reported with darunavir/ritonavir.
Darunavir/ritonavir:-Common (1% to 10%): Rash (including macular, maculopapular, papular, erythematous, pruritic rash), pruritus, lipodystrophy (including lipohypertrophy, lipodystrophy, lipoatrophy)-Uncommon (0.1% to 1%): Angioedema, generalized rash, urticaria, night sweats, allergic dermatitis, eczema, erythema, alopecia, hyperhidrosis, Stevens-Johnson syndrome, acne, dry skin, nail pigmentation, herpes simplex-Rare (less than 0.1%): Drug rash with eosinophilia and systemic symptoms (DRESS), erythema multiforme, dermatitis, seborrheic dermatitis, skin lesion, xeroderma-Frequency not reported: Folliculitis, lipoatrophy, toxic skin eruption, dermatitis medicamentosa, skin inflammation, severe skin reactions (in some cases accompanied by fever and/or elevations of transaminases)-Postmarketing reports: Toxic epidermal necrolysis, acute generalized exanthematous pustulosis, DRESSDarunavir/cobicistat:-Very common (10% or more): Rash (including macular, maculopapular, papular, erythematous, pruritic rash, generalized rash, allergic dermatitis; 16%)-Common (1% to 10%): Angioedema, pruritus, urticaria
Darunavir/ritonavir:-Common (1% to 10%): Headache, peripheral neuropathy, dizziness-Uncommon (0.1% to 1%): Lethargy, hypoesthesia, paresthesia, dysgeusia, disturbance in attention, memory impairment, somnolence, vertigo-Rare (less than 0.1%): Syncope, convulsion, ageusia, sleep phase rhythm disturbance-Frequency not reported: Transient ischemic attack, progressive multifocal leukoencephalopathyDarunavir/cobicistat:-Very common (10% or more): Headache
Darunavir/ritonavir:-Common (1% to 10%): Elevated ALT, elevated AST-Uncommon (0.1% to 1%): Hepatitis, acute hepatitis, cytolytic hepatitis, hepatic steatosis, hepatotoxicity, elevated transaminase, elevated blood bilirubin/hyperbilirubinemia, elevated blood alkaline phosphatase, elevated GGT-Frequency not reported: Elevated hepatic enzymeDarunavir/cobicistat:-Common (1% to 10%): Increased hepatic enzyme
Hyperbilirubinemia (Grade 2: less than 1%; Grade 3: less than 1%; Grade 4: less than 1%), and elevated ALT (Grade 2: up to 9%; Grade 3: up to 3%; Grade 4: up to 1%), AST (Grade 2: up to 7%; Grade 3: up to 4.1%; Grade 4: up to 1.2%), and alkaline phosphatase (Grade 2: up to 3.9%; Grade 3: less than 1%) have been reported with darunavir/ritonavir.In patients receiving darunavir/ritonavir, the incidence of side effects and clinical chemistry abnormalities was not higher in those coinfected with hepatitis B or C virus compared with patients who were not coinfected, with the exception of elevated hepatic enzymes.
Darunavir/ritonavir:-Common (1% to 10%): Insomnia-Uncommon (0.1% to 1%): Depression, disorientation, sleep disorder, abnormal dreams, nightmare, anxiety, decreased libido, irritability-Rare (less than 0.1%): Confusion state, altered mood, restlessnessDarunavir/cobicistat:-Common (1% to 10%): Abnormal dreams
Darunavir/ritonavir:-Common (1% to 10%): Asthenia, fatigue-Uncommon (0.1% to 1%): Pyrexia, chest pain, peripheral edema, flushing, malaise, feeling hot, pain-Rare (less than 0.1%): Chills, abnormal feeling, xerosis-Frequency not reported: Rigors, hyperthermiaDarunavir/cobicistat:-Common (1% to 10%): Fatigue-Uncommon (0.1% to 1%): Asthenia
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Myocardial infarction, angina pectoris, prolonged ECG QT, tachycardia, hypertension-Rare (less than 0.1%): Acute myocardial infarction, sinus bradycardia, palpitations
Spontaneous bleeding in patients with hemophilia A and B has been associated with protease inhibitors.  In many of the reported cases, treatment with protease inhibitors was continued or restarted and some patients required additional factor VIII.  A causal relationship between protease inhibitor therapy and these episodes has not been established.
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Thrombocytopenia, neutropenia, anemia, leukopenia-Rare (less than 0.1%): Elevated eosinophil count-Frequency not reported: Decreased white blood cell count, decreased lymphocytes, decreased total absolute neutrophil count, decreased platelets, increased partial thromboplastin time, increased plasma prothrombin timeHIV protease inhibitor therapy:-Frequency not reported: Increased/spontaneous bleeding (including spontaneous skin hematomas, hemarthrosis) in hemophiliacs
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Acute renal failure, renal failure, nephrolithiasis, elevated blood creatinine-Rare (less than 0.1%): Decreased creatinine renal clearance-Frequency not reported: Renal insufficiencyDarunavir/cobicistat:-Common (1% to 10%): Increased blood creatinine
Osteonecrosis has been reported, particularly with commonly known risk factors (e.g., corticosteroid use, alcohol use, severe immunosuppression, higher body mass index), advanced HIV disease, or long-term combination antiretroviral therapy.Increased CPK, myalgia, myositis, and rarely, rhabdomyolysis have been reported with HIV protease inhibitors, especially when coadministered with nucleoside reverse transcriptase inhibitors.
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Myalgia, osteonecrosis, muscle spasms, muscular weakness, arthralgia, pain in extremities, osteoporosis, elevated blood creatine phosphokinase (CPK)-Rare (less than 0.1%): Musculoskeletal stiffness, arthritis, joint stiffness-Frequency not reported: Osteopenia-Postmarketing reports: RhabdomyolysisDarunavir/cobicistat:-Common (1% to 10%): MyalgiaHIV protease inhibitor therapy:-Frequency not reported: Increased CPK, myalgia, myositis, rhabdomyolysis
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Dyspnea, cough, epistaxis, throat irritation-Rare (less than 0.1%): Rhinorrhea-Frequency not reported: Nasopharyngitis, hiccups, pneumonia, upper respiratory tract infection
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Drug hypersensitivity-Frequency not reported: Facial edemaDarunavir/cobicistat:-Common (1% to 10%): Drug hypersensitivity
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Proteinuria, bilirubinuria, dysuria, nocturia, pollakiuria, erectile dysfunction-Frequency not reported: Polyuria
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Immune reconstitution syndromeDarunavir/cobicistat:-Uncommon (0.1% to 1%): Immune reconstitution inflammatory syndromeCombination antiretroviral therapy:-Frequency not reported: Immune reconstitution inflammatory syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Hypothyroidism, elevated blood thyroid stimulating hormone, gynecomastia
Darunavir/ritonavir:-Uncommon (0.1% to 1%): Conjunctival hyperemia, dry eye-Rare (less than 0.1%): Visual disturbance
Blurred vision
dry mouth
flushed, dry skin
fruit-like breath odor
increased hunger
increased thirst
increased urination
skin rash
sweating
troubled breathing
unexplained weight loss
unusual tiredness or weakness
Abdominal or stomach pain or tenderness
acid or sour stomach
belching
blistering, peeling, or loosening of the skin
bloating
chills
clay colored stools
constipation
cough
dark urine
decreased appetite
diarrhea
difficulty with moving
dizziness
excess air or gas in the stomach or intestines
fast heartbeat
fever
full feeling
headache
heartburn
indigestion
itching
joint or muscle pain
lack or loss of strength
light-colored stools
loss of appetite
muscle aching or cramping
nausea and vomiting
passing gas
red skin lesions, often with a purple center
red, irritated eyes
sore throat
sores, ulcers, or white spots in the mouth or on the lips
swelling of the feet or lower legs
swollen joints
unpleasant breath odor
vomiting of blood
yellow eyes or skin
Muscle pain or stiffness
swelling or puffiness of the face
Stuffy or runny nose
Gaining weight around your neck, upper back, breast, face, or waist